DEFA14A: Jasper Therapeutics Issues Supplement to Proxy Statement Clarifying Abstention Treatment for Proposals 3 and 4

Jasper Therapeutics released a supplement to its proxy statement to correct an error regarding the treatment of abstentions on Proposals 3 and 4 for the upcoming Annual Meeting of Stockholders.

Summary

• Jasper Therapeutics, Inc. has issued a supplement to its definitive proxy statement filed on April 22, 2024.
• The supplement addresses an error in the original proxy statement concerning the treatment of abstentions on Proposals Nos. 3 and 4.
• The Annual Meeting of Stockholders is scheduled for June 6, 2024, at 10:00 a.m. Pacific Time.
• The error pertained to the 'Vote Required' section of Proposals 3 and 4, while the correct treatment was disclosed elsewhere in the proxy statement.
• The supplement clarifies that abstentions will not be counted as votes cast for or against the proposals and will have no effect on the outcome of the vote.
• The company urges stockholders to read the supplement in conjunction with the original proxy statement.
• Stockholders who have already voted and do not wish to change their vote need not take further action.
• Stockholders of record as of April 11, 2024, can change their vote before the Annual Meeting through various methods.
• Street name stockholders should contact their broker, bank, or nominee for instructions on changing their vote.
• The company emphasizes the importance of stockholders submitting their votes.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as the company is correcting an error in a timely manner, demonstrating diligence.

Positives

• The company proactively addressed and corrected an error in the proxy statement.
• Clear instructions are provided for stockholders who wish to change their vote.

Negatives

• The proxy statement contained an error requiring a supplement to be issued.

Risks

• The error in the original proxy statement could have caused confusion among stockholders.

Future Outlook

The company continues to seek the vote of Company stockholders on each of the proposals to be voted on at the Annual Meeting as recommended by the Company's Board of Directors in the original filing.

Industry Context

This announcement is a routine correction to a proxy statement, which is a common occurrence in corporate governance.

Stakeholder Impact

• The correction ensures that stockholders have accurate information for voting decisions.

Next Steps

• Stockholders should review the supplement and the original proxy statement.
• Stockholders should submit their votes before the Annual Meeting.

Key Dates

Keywords

Proxy Statement, Jasper Therapeutics, Annual Meeting, Abstentions, Stockholders, Vote, Proposals, Supplement